Long-acting muscarinic antagonists vs. long-acting β (2) agonists in COPD exacerbations: a systematic review and meta-analysis

Benzer Materyaller

• Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
  Yazar:: Miravitlles, Marc, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β(2)-Agonist (LABA) Combinations in COPD
  Yazar:: Sion, Katya Y. J., ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
  Yazar:: Yamada, Hideyasu, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD
  Yazar:: D’Urzo, Anthony D, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β(2)-agonist fixed-dose combinations in COPD
  Yazar:: Siddiqui, Mohd Kashif, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)